RxDoctor Payments Data

Amanuel Sima, MD

Internal Medicine · Beverly Hills, CANPI 1366493744

Payments from drug & device makers

$43,879in general payments, 2019–2025

Across 46 payments — averaging $953.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$32K
  • AstraZeneca$12K
  • United Therapeutics Corporation$166
  • Advanced Respiratory, Inc$125
  • Bayer$110
  • GSK$68
  • plus $303 from 8 others

What the payments were for

  • Food & beverage$856100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$43,879 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$720,813
Medicare patients
481
Services billed
10,727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate110$121,980
EliquisApixaban100$118,350
OzempicSemaglutide64$83,586
XareltoRivaroxaban50$59,506
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$38,554
MyrbetriqMirabegron40$28,549
Janumet XrSitagliptin Phos/Metformin Hcl27$26,755
NamzaricMemantine Hcl/Donepezil Hcl28$22,156
EntrestoSacubitril/Valsartan18$19,863
Breo ElliptaFluticasone/Vilanterol28$16,757
FarxigaDapagliflozin Propanediol13$14,938
LinzessLinaclotide19$10,239
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$9,980
JanumetSitagliptin Phos/Metformin Hcl11$5,877
Fluticasone Propionate233$4,002

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31,543$118,350100 claims
GSKTrelegy Ellipta, Breo Ellipta$68$55,31184 claims
NovartisEntresto$58$19,86318 claims
AstraZenecaFarxiga$11,564$14,93813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Beverly Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →